Lhasa Limited shared knowledge shared progress

Archive

This is a library of Lhasa's blog articles. 

  • Expert review blog
    Clock: less than 5 minutesless than 5 minutes

    Is expert review an essential step when assessing mutagenic potential of drug impurities?

    A provision for the application of ‘expert knowledge’ is mentioned within the ICH M7 guideline. However, as (Q)SAR models continue to be updated and their predictive performance and structural coverage improves, this raises the question of whether expert review is still necessary… 

    05 May 2022

  • Controlling potentially mutagenic impurities – 8 top tips from industry experts
    Clock: less than 5 minutesless than 5 minutes

    Controlling potentially mutagenic impurities – 8 top tips from industry experts

    A key consideration within drug substance synthesis is the potential presence of mutagenic impurities. Potentially mutagenic impurities (PMIs) often arise from reagents which are essential for the synthesis of a final active pharmaceutical ingredient (API) meaning that the risk is therefore often unavoidable. As a result, there is a need to assess the risk posed by mutagenic impurities.
    To discuss this topic in more detail, we were delighted to welcome Andrew Teasdale PhD and Muzaffar Khan PhD, to present at our webinar; Controlling potentially mutagenic impurities - hear from industry experts!

    In case you missed this event, we have summarised the top eight take away tips from the webinar, for quick and easy consumption within this article. 

    04 April 2022

  • Replace reduce refine
    Clock: less than 5 minutesless than 5 minutes

    Replace, Reduce, Refine - How Lhasa Limited are supporting the 3Rs

    Last year, a revolutionary guideline on Defined Approaches for Skin Sensitisation (OECD GL No.497) was released by the OECD. It is the first ever guideline that recommends the use of a combination of non-animal methods to predict whether a chemical can cause skin allergies. Since the publication of this guideline, Lhasa Limited have developed ‘Skin Sensitisation Defined Approach ITSv1 1.0’ – a web application containing one of the defined approaches published by the OECD, which provides hazard and potency skin sensitisation predictions without the use of animal tests. This tool is a step towards full replacement of animal testing for skin sensitisation and employs the 3Rs principle.

    02 March 2022

  • Picture of blue pills, tablets, caplets
    Clock: 5 minutes5 minutes

    Nitrites in Excipients Data Sharing Consortium: Supporting Nitrosamine Risk Assessment

    Nitrite analysis of excipients is a new and analytically challenging area, with many organisations working quickly to determine the best practice and techniques to use.

    The Nitrites in Excipients data sharing consortium was established in September 2020 and is part of Lhasa Limited's effort to support the global challenge of nitrosamine risk assessment.

    22 February 2022

  • Predicting N-nitrosamine carcinogenic potency using structure-activity relationships (SARs)
    Clock: less than 5 minutesless than 5 minutes

    Predicting N-nitrosamine carcinogenic potency using structure-activity relationships (SARs)

    This blog article introduces an insightful publication by Lhasa Principal Scientist, Dr. David Ponting and Dr. Kevin Cross from Instem, which investigates whether improvements in structure-activity relationships can more accurately predict N-nitrosamine carcinogenic potency.

    17 December 2021

  • How Derek Nexus and Sarah Nexus meet the 5 OECD principles
    Clock: less than 5 minutesless than 5 minutes

    How Derek Nexus and Sarah Nexus meet the 5 OECD principles

    In this article, we discuss how Derek Nexus and Sarah Nexus meet the 5 OECD principles.

    30 November 2021

  • Meeting ICH S1 and reducing animal testing through AOPs; Have you read this?
    Clock: less than 5 minutesless than 5 minutes

    Meeting ICH S1 and reducing animal testing through AOPs; Have you read this?

    “As Adverse Outcome Pathways (AOPs) move from being an interesting scientific concept, to a useful practical application tool, this is an exciting time for both industry and Lhasa” … Regular Lhasa blog readers will have read this statement within our September blog “Shaping Lhasa Limited’s scientific direction through collaboration”.

    It is with great excitement that this month we can provide you with another pioneering update on the topic of our AOP work; Our paper, “Employing an adverse outcome pathway framework for weight-of-evidence assessment with application to the ICH S1B guidance addendum” has now been published in the Regulatory Toxicology and Pharmacology Journal!

    03 November 2021

  • How to make mutagenicity assessment a simpler task blog image
    Clock: less than 5 minutesless than 5 minutes

    How to make mutagenicity assessment a simpler task

    A key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.

    Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!

    15 September 2021

  • Shaping Lhasa Limited’s scientific direction through collaboration
    Clock: less than 5 minutesless than 5 minutes

    Shaping Lhasa Limited’s scientific direction through collaboration

    “Our technology is designed by scientists, for scientists, in collaboration with industry stakeholders and regulators” …

    At Lhasa Limited we often talk about the importance of industry and regulatory input in shaping our scientific direction. This article discusses a few key areas of involvement and collaboration plus, focuses on a recent example, on the topic of Adverse Outcome Pathways (AOPs). Read on to learn more and find out how you can get involved!

    09 September 2021

  • 20 tips for nitrosamine impurity assessment

    20 tips for nitrosamine impurity assessment

    Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!

    05 August 2021

© 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.